The Alpha Journal — Men’s Health Reporting

Ozempic (semaglutide) does not directly damage kidneys, but can cause acute kidney injury in rare cases, primarily through dehydration from gastrointestinal side effects. Clinical trials show potential long-term kidney protective benefits for diabetic patients, though monitoring is essential for those with pre-existing kidney conditions.

Yes, Ozempic (semaglutide) has been associated with an increased risk of acute pancreatitis, though the overall risk remains relatively low. Clinical studies and post-market surveillance have identified pancreatitis as a potential side effect, occurring in approximately 0.2-1% of patients taking GLP-1 receptor agonists.

Current evidence from clinical trials involving over 16,800 patients shows no increased cancer risk from Ozempic in humans. However, the medication carries a black box warning due to thyroid C-cell tumors observed in rodent studies, and it's contraindicated for patients with a personal or family history of medullary thyroid carcinoma.

Current evidence suggests Ozempic does not directly cause depression in most patients, though some post-marketing reports have raised concerns. Clinical trials show no significant increased risk, but individual responses vary and mental health monitoring is recommended during treatment.

Yes, Ozempic can cause hair loss in some users. This side effect is primarily linked to rapid weight loss, nutritional deficiencies, and metabolic changes rather than direct drug toxicity, typically occurring 2-6 months after starting treatment.

Yes, Ozempic can cause tiredness in some patients, though fatigue is relatively uncommon, affecting approximately 0.4% to 11% of users. The fatigue is often related to reduced calorie intake, blood sugar changes, or adjustment periods rather than a direct drug effect.

Ozempic (semaglutide) works by mimicking the natural hormone GLP-1, which regulates blood sugar by stimulating insulin release, suppressing glucagon, slowing digestion, and reducing appetite through multiple pathways in the body.

Ozempic (semaglutide) is primarily FDA-approved for treating type 2 diabetes by improving blood sugar control, and it's also used off-label for weight management due to its appetite-suppressing effects.

Ozempic is a prescription-only medication available through licensed pharmacies with a valid prescription from a healthcare provider.

Yes, diarrhea is a common side effect of Ozempic (semaglutide), affecting approximately 8.5% of patients who take the medication.

While Ozempic (semaglutide) and Mounjaro (tirzepatide) are both injectable medications for type 2 diabetes, they contain different active ingredients and have distinct mechanisms of action.

Ozempic is primarily used to treat type 2 diabetes in adults and helps manage blood sugar levels while reducing cardiovascular risks in patients with diabetes and heart disease.